HOUSTON and VANCOUVER, BC, Oct. 24, 2020 /PRNewswire/ – ESSA Pharma Inc. (Nasdaq: EPIX) (TSXV: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA’s clinical candidate,…

Leave a Reply

Your email address will not be published. Required fields are marked *